EMA Accepts Merck & Ariad’s Sarcoma Drug Filling

Merck & Co (also known as MSD) and partner Ariad Pharmaceuticals moved a step closer to EU approval for cancer treatment ridaforolimus yesterday when the European Medicines Agency agreed to start reviewing their marketing application for the drug. Ridaforolimus is an experimental oral mTOR inhibitor developed as a treatment for patients with metastatic soft-tissue or

Continue Reading